Wide Ranks

AXSM

Axsome Therapeutics, Inc.

99.65

Top Statistics
Market Cap 4 B Forward PE -71.58 Revenue Growth 81.30 %
Current Ratio 2.44 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -91.87 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -19.19 Enterprise / Revenue 13.87 Price To Sales Trailing12 Months 14.27
Profitability
Profit Margins -91.87 % Operating Margins -44.13 %
Balance Sheet
Total Cash 327 M Total Cash Per Share 6.75 Total Debt 192 M
Total Debt To Equity 207.00 Current Ratio 2.44 Book Value Per Share 1.92
All Measures
Short Ratio 1507.00 % Message Board Id finmb_241907563 Fax 212 320 0245
Shares Short Prior Month 7 M Return On Equity -1.72 City New York
Uuid dc312fd5-deeb-376b-9b93-11451c06c191 Previous Close 97.03 First Trade Date Epoch Utc 1 B
Book Value 1.92 Beta 1.25 Total Debt 192 M
Volume 481648 Price To Book 51.96 Fifty Two Week Low 64.11
Total Cash Per Share 6.75 Total Revenue 338 M Shares Short Previous Month Date 1 B
Target Median Price 125.00 Max Age 86400 Recommendation Mean 1.29
Sand P52 Week Change 0.3133 Operating Margins -44.13 % Target Mean Price 129.41
Net Income To Common -310955008 Short Percent Of Float 0.1900 Implied Shares Outstanding 48 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 581870
Average Volume10days 581870 Total Cash 327 M Next Fiscal Year End 1 B
Revenue Per Share 7.11 Held Percent Insiders 0.1668 Ebitda Margins -72.28 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 97.03 Target Low Price 105.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 91.37 Open 97.77 Free Cashflow -42439752
State NY Dividend Yield 0.00 % Return On Assets -0.2644
Time Zone Short Name EST Trailing Eps -6.58 Day Low 96.50
Address1 One World Trade Center Shares Outstanding 48 M Price Hint 2
Target High Price 180.00 Website https://www.axsome.com 52 Week Change 0.4774
Average Volume 485076 Forward Eps -2.16 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 230.10 % Is_sp_500 False
Regular Market Day High 100.48 Profit Margins -91.87 % Debt To Equity 207.00
Fifty Two Week High 105.00 Day High 100.48 Shares Short 7 M
Regular Market Open 97.77 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 13.87 Revenue Growth 81.30 % Shares Percent Shares Out 0.1586
Operating Cashflow -132570000 Currency USD Time Zone Full Name America/New_York
Market Cap 4 B Is_nasdaq_100 False Zip 10007
Quote Type EQUITY Industry Biotechnology Long Name Axsome Therapeutics, Inc.
Regular Market Day Low 96.50 Held Percent Institutions 0.8107 Current Price 99.65
Address2 22nd Floor Enterprise To Ebitda -19.19 Financial Currency USD
Current Ratio 2.44 Gross Margins 91.09 % Industry Disp Biotechnology
Number Of Analyst Opinions 17 Country United States Float Shares 36 M
Two Hundred Day Average 82.67 Enterprise Value 4 B Price To Sales Trailing12 Months 14.27
Forward PE -71.58 Regular Market Volume 481648 Ebitda -244623008
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.

Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation.

The company was incorporated in 2012 and is based in New York, New York.